An observational study in Microscopic Polyangiitis (MPA) and Granulomatosis With Polyangiitis (GPA), sponsored by Kissei Pharmaceutical Co., Ltd.. Recruiting at 1 site in Japan. Per ClinicalTrials.gov, last updated 2025-01-17.
Sponsored by Kissei Pharmaceutical Co., Ltd. · Observational
The purpose of this survey is evaluating the safety and efficacy of long-term administration of avacopan for Japanese patients with microscopic polyangiitis or granulomatosis with polyangiitis under actual conditions of use.
The purpose of this survey is evaluating the safety and efficacy of long-term administration of avacopan for Japanese patients with microscopic polyangiitis or granulomatosis with polyangiitis under actual conditions of use.
Patients with granulomatosis with polyangiitis or microscopic polyangiitis who are treatment with avacopan
Inclusion Criteria:
Drug: Avacopan
oral administration
Adverse events
Time frame: 2 years
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Granulomatosis with Polyangiitis→
Kissei Pharmaceutical Co., Ltd.